30 closest matches · ranked by relevance
Arthralgia · Musculoskeletal Complications · Pain
Primary: Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness — 12; 1…
Breast Cancer
Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL
Breast Cancer
Primary: Disease-free Survival — 88; 88; 87 percentage of analyzed participants — p=0.49
Arthralgia · Breast Cancer · Pain
Primary: Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score — 5.3; 5.47 BPI score — p=0.58
Ductal Carcinoma in Situ · Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-positive Breast Cancer
Primary: Number of Participants With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) — 22 Participants — p=<0.001
Breast Cancer · Lung Cancer · Metastatic Cancer
Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844
Malignant Neoplasm · Metastatic Malignant Neoplasm in the Bone · Pain
Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325
Breast Cancer · Osteoporosis
Primary: Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD) — 2.66 Percentage of the baseline value — p=0.01
Breast Cancer
Primary: Disease Free Survival. — 81.0; 79.6 percentage of patients
Early Breast Cancer
Primary: Number of Participants With New Events of Arthralgia — 37 Participants
Bone Loss · Osteoporosis · Breast Cancer
Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change
Breast Cancer
Primary: Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy — 2.680; -3.314 Percent Change
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
Osteoporosis · Breast Cancer
Primary: Mean Percent Change in Total Volumetric Bone Mineral Density (BMD) Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-PQCT) From Baseline to 24…
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants
Breast Cancer
Primary: Change in Bone Mineral Density (BMD) From Baseline to 1 Year — 0.048; 0.007; 0.014; 0.005 grams per cubic centimeter
Breast Cancer
Primary: Maximum Patient-reported Bone Pain in Cycle 1 — 3.2; 3.5 units on a scale — p=0.3479
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
Bone Loss · Breast Cancer
Primary: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy. — 2.208; -3.617 Percentage change in BMD
Breast Cancer · Arthralgia · Obesity
Primary: Effect of Change in Body Mass Index on Change in Grip Strength With Aromatase Inhibitor Therapy — -0.15; 2.44 kg/m^2 — p=0.03
Breast Cancer · Other Disorders of Bone Density and Structure
Primary: Mean Percentage Change in Lumbar Spine Bone Mineral Density From Baseline (Before Chemotherapy Commencement) to Month 12 of AI Therapy — -0.72 percentage of change
Breast Cancer · Musculoskeletal Complications · Pain
Primary: Average Joint Pain According to BPI-SF — 2.9; 3.5 units on a scale — p=0.0002
Breast Cancer
Primary: Mean Change in Bone Resorption: NTX (N-terminal Telopeptide) — NA nmol
Breast Cancer · Metastatic Cancer
Primary: Progression-free Survival — 10.3; 15.3 weeks
Breast Cancer · Metastatic Bone Disease
Primary: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 — -73; -77 Percentage change
Breast Cancer With Bone Metastasis
Primary: Annual Overall Skeletal Morbidity Rate (SMR) — 0.26; 0.22 Number of Skeletal Events per Year
Breast Neoplasms · Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) — 1.955; -2.325 Percentage of BMD
Breast Cancer · Pain · Arthralgia
Primary: Mean Pain50 Assessed at Baseline, 3 Months and 6 Months — 4.3; 4.2; 4.2 kg/cm^2
Metastatic Cancer · Pain
Primary: Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment — 28.0; 32.0 percentage of participants — p=0.03